High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Open Access
- 15 June 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 99 (12), 4357-4363
- https://doi.org/10.1182/blood.v99.12.4357
Abstract
Nonmyeloablative conditioning is increasingly used for transplantation in a wide range of diseases, but little is known about its impact on the incidence of infections and immune reconstitution. We examined the pattern and outcome of cytomegalovirus (CMV) infections monitored by polymerase chain reaction–based assays and treated preemptively in 101 patients following nonmyeloablative conditioning containing in vivo Campath-1H. Fifty-one patients (50%) had a CMV infection at a median of 27 days after transplantation with a probability of 84.8% in patients at risk of CMV infection. The probability of recurrence of CMV infection before and after 100 days was 53.6% and 46.6%, respectively, and was more common in unrelated donor transplant recipients. All 3 patients who developed CMV disease died of this complication. The 2 patients with late CMV disease had grade III to IV graft-versus-host-disease (GVHD), which occurred de novo in only 4% of patients and in another 10% following donor lymphocyte infusions. The median time to CD4+ T-cell count more than 200/μL was 9 months in the 48 patients studied. The probabilities of overall survival and nonrelapse mortality at 18 months were 65% and 27.8%, respectively, with no significant difference in survival between CMV-infected and -uninfected patients. The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis.Keywords
This publication has 22 references indexed in Scilit:
- Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomesBlood, 2001
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantationBlood, 2001
- Non-myeloablative stem cell transplants. AnnotationBritish Journal of Haematology, 2000
- A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapyBone Marrow Transplantation, 2000
- High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantationBone Marrow Transplantation, 2000
- Mixed chimerism: Preclinical studies and clinical applicationsTransplantation and Cellular Therapy, 1999
- Late Cytomegalovirus Pneumonia in Adult Allogeneic Blood and Marrow Transplant RecipientsClinical Infectious Diseases, 1999
- Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experienceBone Marrow Transplantation, 1998
- Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV diseaseBone Marrow Transplantation, 1998
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986